Company Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities.
The company was founded in 2018 and is based in Carmel, Indiana.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Peter Hawryluk |
Contact Details
Address: 11711 North Meridian Street, Suite 300 Carmel, Indiana 46032 United States | |
| Phone | 317 659 0200 |
| Website | mbxbio.com |
Stock Details
| Ticker Symbol | MBX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001776111 |
| CUSIP Number | 55287L101 |
| ISIN Number | US55287L1017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Kent Hawryluk MBA | Chief Executive Officer, President and Director |
| Steven L. Hoerter | Executive Chairperson |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer |
| John W. Smither CPA | Interim Chief Financial Officer |
| Pete De Spain | Senior Vice President of Investor Relations and Corporate Communications |
| Michelle Graham | Chief Human Resources Officer |
| Dr. Michael A. Dorato DABT, Ph.D. | Senior Vice President of Discovery and Non-Clinical Development |
| Dr. Chatan Charan Ph.D. | Senior Vice President of Pharmaceutical Development and Chemistry, Manufacturing and Controls |
| Mark Hope | Senior Vice President of Regulatory and Quality |
| Dr. Andreas Moraitis M.D. | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |
| Apr 22, 2026 | 144 | Filing |
| Apr 22, 2026 | ARS | Filing |
| Apr 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2026 | 144 | Filing |
| Mar 16, 2026 | 144 | Filing |
| Mar 12, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2026 | 10-K | Annual Report |